This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kotliarova, S. Articles by Fine, H. A. Search for Related Content PubMed PubMed Citation Articles by Kotliarova, S. Articles by Fine, H. A.

Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor-B, and Glucose Regulation

¹ Neuro-Oncology Branch, National Cancer Institute and ² National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland

Requests for reprints: Howard A. Fine, Neuro-Oncology Branch, National Cancer Institute, Room 225, The Bloch Building (#82), 9030 Old Georgetown Road, Bethesda, MD 20892. Phone: 301-402-6383; Fax: 301-480-2246; E-mail: hfine{at}mail.nih.gov.

Key Words: GSK3 • NF-B • c-MYC • glucose

Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, is involved in diverse cellular processes ranging from nutrient and energy homeostasis to proliferation and apoptosis. Its role in glioblastoma multiforme has yet to be elucidated. We identified GSK3 as a regulator of glioblastoma multiforme cell survival using microarray analysis and small-molecule and genetic inhibitors of GSK3 activity. Various molecular and genetic approaches were then used to dissect out the molecular mechanisms responsible for GSK3 inhibition–induced cytotoxicity. We show that multiple small molecular inhibitors of GSK3 activity and genetic down-regulation of GSK3/β significantly inhibit glioma cell survival and clonogenicity. The potency of the cytotoxic effects is directly correlated with decreased enzyme activity–activating phosphorylation of GSK3/β Y276/Y216 and with increased enzyme activity inhibitory phosphorylation of GSK3 S21. Inhibition of GSK3 activity results in c-MYC activation, leading to the induction of Bax, Bim, DR4/DR5, and tumor necrosis factor-related apoptosis-inducing ligand expression and subsequent cytotoxicity. Additionally, down-regulation of GSK3 activity results in alteration of intracellular glucose metabolism resulting in dissociation of hexokinase II from the outer mitochondrial membrane with subsequent mitochondrial destabilization. Finally, inhibition of GSK3 activity causes a dramatic decrease in intracellular nuclear factor-B activity. Inhibition of GSK3 activity results in c-MYC–dependent glioma cell death through multiple mechanisms, all of which converge on the apoptotic pathways. GSK3 may therefore be an important therapeutic target for gliomas. Future studies will further define the optimal combinations of GSK3 inhibitors and cytotoxic agents for use in gliomas and other cancers. [Cancer Res 2008;68(16):6643–51]

This article has been cited by other articles:

				T. N. Kreisl, L. Kim, K. Moore, P. Duic, S. Kotliarova, J. Walling, L. Musib, D. Thornton, P. S. Albert, and H. A. Fine A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas Clin. Cancer Res., May 15, 2009; 15(10): 3617 - 3623. [Abstract] [Full Text] [PDF]

				Y. Kotliarov, S. Kotliarova, N. Charong, A. Li, J. Walling, E. Aquilanti, S. Ahn, M. E. Steed, Q. Su, A. Center, et al. Correlation Analysis between Single-Nucleotide Polymorphism and Expression Arrays in Gliomas Identifies Potentially Relevant Target Genes Cancer Res., February 15, 2009; 69(4): 1596 - 1603. [Abstract] [Full Text] [PDF]